Emergent BioSolutions

EBS · NYSE

$6.29−$0.07 (−1.10%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $6.36

About EBS

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. The company is headquartered in Gaithersburg, Maryland and currently employs 900 full-time employees. The company went IPO on 2006-11-15. The company is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.

Employees: 900
Headquarters: Gaithersburg, Maryland
Listed: Nov 15, 2006
Sector: Health Care
Industry: Biotechnology
Website: emergentbiosolutions.com

Leadership

Emergent BioSolutions executives
Name	Title	Since	Age
Zsolt Harsanyi	—	—	81
Joseph Papa	—	2024	69
Richard Lindahl	—	—	61
Coleen Glessner	—	—	54
Jessica Perl	—	—	44
William Hartzel	—	—	47
Paul Williams	—	—	58
Simon Lowry	—	—	52
Sujata Dayal	—	—	62
Donald Degolyer	—	—	63
John Fowler	—	—	62
Neal Fowler	—	—	63
Keith Katkin	—	—	53
Ronald Richard	—	—	69
Marvin White	—	—	63
Kathryn Zoon	—	—	76

Revenue by product and region

Fiscal year ended Dec 31, 2025: $742.90M total revenue

By product

Contracts and grants$37.70M5.1%
Product and services sales, net$1.90M0.3%

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Emergent BioSolutions suppliers and customers
Company	Relationship	Country	Correlation
Humanigen HGEN	Supplier and customer	US	0.86
Vaxart VXRT	Supplier and customer	US	0.84
Aridis Pharmaceuticals ARDS	Supplier and customer	US	0.83
Soligenix SNGX	Supplier and customer	US	0.78
ChemoMetec CHEMM.CO	Supplier	DK	0.40
Kamada KMDA	Supplier and customer	IL	0.01
Johnson & Johnson JNJ	Customer	US	-0.19
Opiant Pharmaceuticals OPNT	Supplier and customer	US	-0.40
Merck & Co MRK	Supplier and customer	US	-0.55
AstraZeneca AZN.L	Customer	GB	-0.63

Similar companies

Companies in the same industry as Emergent BioSolutions

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.